AI Analysis
AI-generated analysis. Always verify with the original filing.
Cardiol Therapeutics announced its year-end 2025 operational update, highlighting accelerated enrollment in the pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis, positive Phase II ARCHER results in acute myocarditis, advancement of the CRD-38 program toward Phase I, U.S. patent protection extension, board strengthening, and a strengthened cash runway into Q4 2027.
Key Takeaways
1The pivotal Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis surpassed 50% patient enrollment, with full enrollment expected in Q2 2026, supporting a potential New Drug Application.
2Positive Phase II ARCHER trial results demonstrated CardiolRx™ significantly reduced left ventricular mass in acute myocarditis patients, with data published in ESC Heart Failure.
3The CRD-38 program for heart failure advanced toward an Investigational New Drug Application and Phase I clinical development.
4The company received a U.S. patent allowance broadly protecting CardiolRx™ and CRD-38 for use in treating cardiac conditions through October 2040.
5Dr. Timothy J. Garnett, former Chief Medical Officer of Eli Lilly and Company, was elected to the Board of Directors in May 2025.
6Aggregate gross proceeds of approximately $31 million from financings provide a cash runway into Q4 2027.